Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nectar LifesciencesNSE:NECLIFE +4.98%36 Gross Margin % is 5.52% as of Jun. 2026, which is 68% below its 10-year median of 17.17. GuruFocus rates NSE:NECLIFE with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 939 Drug Manufacturers companies, Nectar Lifesciences ranks worse than 76.78% on this metric.
The historical rank and industry rank for Nectar Lifesciences's Gross Margin % or its related term are showing as below:
NSE:NECLIFE'
s Gross Margin % Range Over the Past 10 Years
Min: 12.62 Med: 17.17 Max: 32.79
Current: 32.79
During the past 13 years, the highestGross Margin % of Nectar Lifesciences was 32.79%. The lowest was 12.62%. And the median was 17.17%.
NSE:NECLIFE's Gross Margin % is ranked worse than 76.78% of 939
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:NECLIFE: 32.79
Nectar Lifesciences had a gross margin of 5.52% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nectar Lifesciences was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nectar Lifesciences had a gross margin of 5.52% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nectar Lifesciences Gross Margin % Related Terms
Nectar Lifesciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nectar Lifesciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nectar Lifesciences Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nectar Lifesciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nectar Lifesciences (NSE:NECLIFE) has a Gross Margin % of 5.52% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nectar Lifesciences and its competitors. This is 68% below median its historical median of 17.17. Over the past decade, Nectar Lifesciences' Gross Margin % has ranged from 12.62 to 32.79. According to the industry distribution chart, Nectar Lifesciences ranks #721 out of 939 companies in the Drug Manufacturers industry, placing it in the top 76.8%.
Is Nectar Lifesciences' Gross Margin % too high?
Nectar Lifesciences' current Gross Margin % of 5.52% is 68% below median its 10-year median of 17.17. Over the past 10 years, this metric has ranged from a low of 12.62 to a high of 32.79. The Drug Manufacturers industry median Gross Margin % is 48.54. Nectar Lifesciences' value of 5.52% is 88.6% below this industry median. Based on the distribution chart, Nectar Lifesciences ranks #721 out of 939 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nectar Lifesciences has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nectar Lifesciences ranks #721 out of 939 companies for Gross Margin %. This places Nectar Lifesciences in the lower half of its industry. The industry median Gross Margin % is 48.54. Nectar Lifesciences' value of 5.52% is 88.6% below this benchmark. Historically, Nectar Lifesciences' own Gross Margin % has ranged from 12.62 to 32.79 over the past decade. While the company's 10-year median is 17.17 vs. the industry median of 48.54, Nectar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nectar Lifesciences's current Gross Margin % of 5.52% is 88.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nectar Lifesciences and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nectar Lifesciences's current Gross Margin % is 5.52%, which is 68% below median its own 10-year median of 17.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Nectar Lifesciences (NSE:NECLIFE) has a current Gross Margin % of 5.52%. The current Gross Margin % is 5.52%, which is 68% below median its 10-year median of 17.17 and 88.6% below the Drug Manufacturers industry median of 48.54. Nectar Lifesciences' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Gross Margin % is 5.52% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
36GF Score
Get the complete analysis for NSE:NECLIFE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NECLIFE has been successfully added to your 
